Home General Biotechnology Get a Free DrugPatentWatch Report

Get a Free DrugPatentWatch Report

Get a free DrugPatentWatch Report

As a special bonus for BiotechBlog readers, you can get a free DrugPatentWatch report when you sign up for a one-year Ultimate Plan or Premium Plan subscription by January 29, 2012.

The following reports are available through this special offer:

Drug Patent Challenge Report
The Drug Patent Challenge Report profiles the companies that successfully challenged pharmaceutical drug patents since 2000.

  • The companies with the most successful patent challenges
  • The drugs for which each firm successfully challenged a patent
  • The companies that have received FDA approval for each listed drug
  • More than 60 companies profiled
  • More than 80 drugs profiled

Currently selling for $800 in the DrugPatentWatch Report Store.

Orphan Drug Report
The Orphan Drug Report profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity since 2000.

  • The tradename, applicant, ingredient, and Orphan exclusivity expiration dates for each Orphan Drug
  • Details on each NDA and product number, including Dosage, Strength, Approval Date, Therapeutic Equivalence (TE) code, Reference Listed Drug (RLD) indicator
  • All FDA-listed patents covering each Orphan Drug
  • More than 100 pages
  • More than 80 drugs profiled

Currently selling for $500 in the DrugPatentWatch Report Store.

Individual Country Drug Patent Inventor Reports
These Individual Country Drug Patent Inventor Reports profile the individuals who have been awarded pharmaceutical drug patents since 2000.

    Individual country profiles available for:

  • Australia
  • Belgium
  • Canada
  • China
  • Denmark
  • Finland
  • France
  • Germany
  • Ireland
  • Israel
  • Italy
  • Japan
  • Netherlands
  • Norway
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom
  • United States

These reports currently sell for $195 to $795 in the DrugPatentWatch Report Store.

To take advantage of this offer:

 

NO COMMENTS

Leave a Reply